TY - JOUR
T1 - Phosphorylation of Akt (Ser473) predicts poor clinical outcome in oropharyngeal squamous cell cancer
AU - Yu, Ziwei
AU - Weinberger, Paul M.
AU - Sasaki, Clarence
AU - Egleston, Brian L.
AU - Speier IV, William F.
AU - Haffty, Bruce
AU - Kowalski, Diane
AU - Camp, Robert
AU - Rimm, David
AU - Vairaktaris, Eleftherios
AU - Burtness, Barbara
AU - Psyrri, Amanda
PY - 2007/3
Y1 - 2007/3
N2 - Background: Several lines of laboratory evidence support a role of persistent activation of Akt pathway in oropharyngeal squamous cell carcinoma (OSCC) progression. Loss of phosphatase PTEN is one of the proposed mechanisms of Akt activation. We sought to determine the prognostic significance of Akt activation in a cohort of patients with OSCC as well as the association between phosphorylated (activated) Akt and PTEN levels. Methods: Using a novel system of in situ quantitative protein expression analysis (AQUA), we studied the protein expression levels of phosphorylated Akt (p-Akt) and PTEN on a tissue microarray. The array included 79 OSCCs with a mean follow-up of 36 months. Results: Patients with tumors expressing low tumor p-Akt levels had lower 5-year local recurrence rates (5% versus 38%). Additionally, these patients had improved 5-year overall survival rates (45% versus 27%). This survival effect was likely due to disease recurrence, as there was no difference in death without recurrence between low-and high-expressing groups. In adjusted analysis, tumor p-Akt expression was a strong predictor of local recurrence. A significant inverse relationship was found between nuclear p-Akt and nuclear PTEN: Tumors with high nuclear p-Akt had low nuclear PTEN and vice versa. Conclusions: Akt activation in OSCC is associated with adverse patient outcome, indicating that Akt is a promising molecular target in OSCC. PTEN loss may be one of the mechanisms of Akt activation in OSCC.
AB - Background: Several lines of laboratory evidence support a role of persistent activation of Akt pathway in oropharyngeal squamous cell carcinoma (OSCC) progression. Loss of phosphatase PTEN is one of the proposed mechanisms of Akt activation. We sought to determine the prognostic significance of Akt activation in a cohort of patients with OSCC as well as the association between phosphorylated (activated) Akt and PTEN levels. Methods: Using a novel system of in situ quantitative protein expression analysis (AQUA), we studied the protein expression levels of phosphorylated Akt (p-Akt) and PTEN on a tissue microarray. The array included 79 OSCCs with a mean follow-up of 36 months. Results: Patients with tumors expressing low tumor p-Akt levels had lower 5-year local recurrence rates (5% versus 38%). Additionally, these patients had improved 5-year overall survival rates (45% versus 27%). This survival effect was likely due to disease recurrence, as there was no difference in death without recurrence between low-and high-expressing groups. In adjusted analysis, tumor p-Akt expression was a strong predictor of local recurrence. A significant inverse relationship was found between nuclear p-Akt and nuclear PTEN: Tumors with high nuclear p-Akt had low nuclear PTEN and vice versa. Conclusions: Akt activation in OSCC is associated with adverse patient outcome, indicating that Akt is a promising molecular target in OSCC. PTEN loss may be one of the mechanisms of Akt activation in OSCC.
KW - Adult
KW - Aged
KW - Biomarkers, Tumor/analysis
KW - Carcinoma, Squamous Cell/metabolism
KW - Chi-Square Distribution
KW - Female
KW - Humans
KW - Immunoenzyme Techniques
KW - Male
KW - Middle Aged
KW - Neoplasm Recurrence, Local
KW - Oropharyngeal Neoplasms/metabolism
KW - PTEN Phosphohydrolase/metabolism
KW - Phosphorylation
KW - Predictive Value of Tests
KW - Prognosis
KW - Proportional Hazards Models
KW - Protein Array Analysis/methods
KW - Proto-Oncogene Proteins c-akt/metabolism
KW - Survival Analysis
UR - http://www.scopus.com/inward/record.url?scp=34047247690&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000245093900032&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1158/1055-9965.EPI-06-0121
DO - 10.1158/1055-9965.EPI-06-0121
M3 - Article
C2 - 17372251
SN - 1055-9965
VL - 16
SP - 553
EP - 558
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 3
ER -